Celsion Corporation (NASDAQ:CLSN)‘s stock had its “hold” rating reaffirmed by Maxim Group in a research report issued to clients and investors on Monday.

CLSN has been the subject of several other research reports. Zacks Investment Research upgraded shares of Celsion Corporation from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a research note on Wednesday, April 26th. Rodman & Renshaw restated a “buy” rating and set a $21.00 price target on shares of Celsion Corporation in a research note on Monday, April 10th. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of Celsion Corporation in a research note on Monday, April 10th. Finally, ValuEngine upgraded shares of Celsion Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, May 31st. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $25.38.

Shares of Celsion Corporation (NASDAQ CLSN) traded down 11.7484% during midday trading on Monday, hitting $1.3679. The company had a trading volume of 572,418 shares. The company’s 50-day moving average price is $2.09 and its 200 day moving average price is $0.94. The company’s market capitalization is $5.57 million. Celsion Corporation has a 12-month low of $1.30 and a 12-month high of $19.60.

Celsion Corporation (NASDAQ:CLSN) last issued its quarterly earnings results on Thursday, May 18th. The biotechnology company reported ($1.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.30) by $0.34. Celsion Corporation had a negative return on equity of 201.04% and a negative net margin of 4,299.60%. The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million. Equities research analysts predict that Celsion Corporation will post ($2.79) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/07/maxim-group-reiterates-hold-rating-for-celsion-corporation-nasdaqclsn.html.

A hedge fund recently raised its stake in Celsion Corporation stock. Renaissance Technologies LLC raised its position in shares of Celsion Corporation (NASDAQ:CLSN) by 396.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 684,798 shares of the biotechnology company’s stock after buying an additional 546,813 shares during the period. Renaissance Technologies LLC owned about 2.63% of Celsion Corporation worth $208,000 as of its most recent filing with the SEC. 92.60% of the stock is owned by institutional investors and hedge funds.

About Celsion Corporation

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.